Compare McKesson Corporation (MCK) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Invesco S&P 500 Momentum ETF — how do they compare? McKesson Corporation trades at $940.73 (market cap $108.46B), while Invesco S&P 500 Momentum ETF trades at $151.49 (market cap $23.48B). The key difference: McKesson Corporation is far larger — about 4.6× Invesco S&P 500 Momentum ETF's market cap, and McKesson Corporation pays a 0.4% dividend while Invesco S&P 500 Momentum ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Invesco S&P 500 Momentum ETF for 54 Days on average.
| MCK | SPMO | |
|---|---|---|
Market Cap | $108.46B | $23.48B |
Volume | 712,607 | 1,876,152 |
Sector | Health | Broad Market / Factor |
52-Week High | $995.69 | $161.66 |
52-Week Low | $725.17 | $107.84 |
Typical Hold Time | 74 Days | 54 Days |
Enterprise Value | $115.00B | — |
Dividend Yield | 0.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $937.98, up 3.04% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent positive developments include the CVS Health partnership extension through 2032 and raised full-year guidance. Revenue growth remains robust at $359.05 billion for 2025, though net margins are thin at 1.12%.
The outlook remains positive with 81% analyst buy ratings and a $956.43 consensus target. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. Strong cash flow generation ($6.09B operating cash flow) supports the dividend and growth initiatives, while technical indicators show the stock testing resistance near $938.
SPMO trades at $153.00, showing minimal daily movement with a 0.01% gain. The ETF maintains a bullish technical outlook with strong moving average signals, though oscillators suggest neutral momentum. Recent portfolio reconstitution added 54 stocks including Apple and Merck, while removing Nvidia. Institutional interest remains strong with Envestnet Asset Management increasing its stake by 9.5% in Q2 2026.
The momentum-focused ETF offers concentrated exposure to S&P 500's fastest-rising stocks, historically outperforming the broader index. Key risks include sector concentration in technology and higher volatility. Analyst sentiment remains positive given the fund's structural momentum advantage and institutional accumulation trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
